MK-677: a beginner's guide to the oral GH secretagogue

Key takeaways

• MK-677, also called ibutamoren, is a lab-made pill, not a peptide. It is a small molecule you swallow that signals your body to release more of its own growth hormone, and it has no approved medical use .
• Unlike most research compounds, MK-677 has real multi-year human trials. In a 2-year study of 65 healthy adults aged 60 to 81, 25 mg a day raised growth hormone and IGF-1 to healthy young-adult levels and added about 1.1 kg of fat-free mass, but that gain did not improve strength or function .
• A separate trial in 123 elderly hip-fracture patients was stopped early over a congestive-heart-failure safety signal, and the drug was judged to have an unfavorable safety profile in that group .
• The consistent downsides across trials are water retention and swelling, higher fasting blood sugar (about 5 mg/dL in the 2-year trial), and lower insulin sensitivity .
• It is not FDA-approved, its development was never carried to approval, and it is on the World Anti-Doping Agency Prohibited List, so any drug-tested athlete would fail a test .

The short version: well-studied, and then abandoned

MK-677 (its research name is ibutamoren, sometimes written MK-0677) is a small molecule you take by mouth, as a tablet or a measured liquid . That single fact is where beginners go wrong: almost everything it gets lumped in with is an injectable peptide, and MK-677 is neither injectable nor a peptide .

It belongs to a group called growth hormone secretagogues. A secretagogue does not add hormone from outside the body; it tells the pituitary to release more of the growth hormone you already make, in MK-677's case by acting like ghrelin, the hunger hormone . It gets filed next to peptides like ipamorelin because they do the same job, but MK-677 is the rare oral, non-peptide one, and that is its main selling point: no needles.

What people actually use it for

In peptide and gym circles, MK-677 gets used for deeper sleep, a higher IGF-1 number on bloodwork, more appetite, and slow gains in lean body mass. Two of those, the appetite bump and the lean-mass gain, line up with the trial data. The sleep and physique claims are mostly community reports .

Two honest caveats sit under all of it. First, the trial that added lean mass also found the extra tissue did not improve strength or physical function, so a higher IGF-1 number on a lab report is not the same as getting stronger . Second, every trial was run in older or short-term populations, so the results a healthy 25-year-old is chasing were never actually measured in people like them.

The human trials are real, and they did not say what people hope

The evidence for MK-677 is genuinely deeper than for most research peptides. The core study is a 2-year randomized trial in 65 healthy adults aged 60 to 81, taking 25 mg a day. It raised growth hormone and IGF-1 into the range of healthy young adults and increased fat-free mass by 1.1 kg, against a 0.5 kg drop on placebo, with no meaningful change in fat mass .

That is a real, measured effect on body composition. What it did not do was improve strength or physical function . A body-composition number that does not translate into being stronger or functioning better is a hard thing to approve a drug on, and MK-677 never was .

The catch: fluid, blood sugar, a heart-failure signal, and a ban

• Water retention and swelling. The most frequent side effects in the 2-year trial were an appetite increase that faded after a few months and mild, temporary swelling in the lower legs . Puffiness and a few pounds of water are expected, not a surprise.
• Blood sugar moves the wrong way. Fasting glucose rose by about 5 mg/dL and insulin sensitivity dropped in that same trial . If you already carry blood-sugar or metabolic risk, that is worth watching, and it is a reason to actually check fasting glucose and HbA1c rather than guess.
• The heart-failure signal is why the drug is gone. The hip-fracture trial was halted early over a congestive-heart-failure imbalance against placebo . That was in frail elderly patients, so do not read it as proven heart damage at community doses, but it is the single reason development stopped, and it is not something to dismiss.
• Warning signs to act on. Because those overlap with early heart-failure symptoms, stop and get checked by a clinician for swelling that will not go down, shortness of breath, or unexplained fatigue.
• Not what people assume. MK-677 is not a peptide, not a form of growth hormone, and not hormone-replacement therapy. It is an unapproved small-molecule drug that no regulator has cleared for human use .
• Banned in sport. MK-677 is on the World Anti-Doping Agency Prohibited List . Growth hormone secretagogues are prohibited at all times, in and out of competition, so any tested athlete, from NCAA to Olympic level, would fail a test.
• What is in the product is unverified. Because it is unapproved and sold as a research chemical, no regulator checks that a given tablet or bottle holds what the label says, or how much .

How people take it, and where the real numbers live

The useful thing to know first is that MK-677 is the simple one to take: oral, once a day, as a tablet or a measured liquid. There is no vial to reconstitute, no bacteriostatic water, no syringe math, which is exactly why people pick it over the injectable secretagogues .

Because the effects that matter most are metabolic, the most useful thing a beginner can do is measure. A fasting glucose and an HbA1c before you start, and again a few weeks in, will tell you more about whether MK-677 suits your body than any dose you copy from someone else, since raised fasting glucose and lower insulin sensitivity are the documented, repeatable effects .

Where to read more

This guide is the on-ramp. There is no dedicated MK-677 deep dive yet, so the closest read is CJC-1295 and ipamorelin vs pharmaceutical HGH, which weighs the whole growth-hormone-secretagogue idea against actual prescription HGH and is the best place to see where an oral option like MK-677 fits. If you are comparing it to the injectable peptides it gets shelved next to, the ipamorelin beginner guide and the CJC-1295 beginner guide cover those. For a wider reality check on the class, peptide hype versus safety is worth the time. The MK-677 library entry is the quick reference for dose ranges, schedule, and sources.

How we sourced this, and the fine print

Every claim on this page is pinned to a published source: the 2-year body-composition trial, the hip-fracture safety trial, the early pharmacology paper, and the US Department of Defense advisory that covers its legal and anti-doping status. Where the effect people want was never actually measured in people, this guide says so instead of guessing.

For research and educational purposes only. Not medical advice.

pepSmart has not commissioned independent clinical review of this article.

More on how we write and source these guides: Editorial process and contributor disclosure and Sourcing posture.

Spot an error? Email corrections via /about.

Sources: 4 entries, all primary or authoritative government sources (PubMed and the US Department of Defense's Operation Supplement Safety), last reviewed 2026-07-13.

Related tools

• Peptide reconstitution calculator - Convert vial mass and BAC water volume into mcg/ml.
• BAC water calculator - Solve BAC water volume for a target concentration.
• Multi-dose vial calculator - Estimate doses per vial and a projected vial-empty date.
• Reconstituted-vial storage window calculator - Estimate a generic usable-window date and days remaining.
• Peptide half-life calculator - Estimate single-dose decay from cited half-life constants.